In this issue:
Bictegravir/FTC/TAF vs dolutegravir/abacavir/lamivudine
Bictegravir/FTC/TAF vs dolutegravir/FTC/TAF
Cancer risk in HIV-infected people
HIV-1 infection during tenofovir diphosphate PrEP
Urgent vs post-stabilisation ART in hospitalised HIV-infected children
Dolutegravir as maintenance monotherapy for HIV
Switching HIV maintenance therapy in high cardiovascular risk
HIV and depression: antidepressants and viral suppression
Response of drug-naive HIV-1-infected patients on first-line therapy
Acute alcohol consumption and HIV transmission risk
Please login below to download this issue (PDF)